



Immunobiologically relevant level of aflatoxin B₁ alters transcription of key functional immune genes, phagocytosis and survival of human dendritic cells

Jalil Mehrzad^{a,b,*,1}, Abbas Bahari^{b,1,2}, Mohammad Reza Bassami^c, Mahmoud Mahmoudi^d, Hesam Dehghani^e

^a Section Immunology, Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

^b Department of Pathobiology, Sections Immunology and Biotechnology, Faculty of Veterinary Medicine, and Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran

^c Department of Basic Sciences, Faculty of Veterinary Medicine, and Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran

^d Immunology Research Center, Department of Immunology and Allergy, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

^e Department of Clinical Science, Faculty of Veterinary Medicine, and Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran

ARTICLE INFO

Keywords:

AFB₁
AFB₁-detoxifying genes
Dendritic cells
Flow cytometry
Functional genes
Immunoderegulation
Phagocytosis
RT-qPCR
Survival

ABSTRACT

The effects of naturally occurring levels of aflatoxin (AF) B₁ on the expression of key molecules and function of dendritic cells (DCs) were investigated on human monocyte-derived DCs (MDDCs) by cell culture, RT-qPCR, and flow cytometry. An environmentally relevant level of AFB₁ remarkably impaired the phagocytic capacity of MDDCs. Furthermore, AFB₁ significantly affected the transcript levels of some key functional genes in MDDCs. It caused an up-regulation of key transcripts in cytochrome P450 (CYP) family, MyD88, NF-κB, TNF-α, TLR2, TLR4, COX-2, HLA-DR, CCR7, CD209, LFA3 and CD16. AFB₁ down-regulated the expression of AhR, TGF-β, CD11c and CD64 within 2–12 h post-exposure. In contrast, the transcription of some other key genes, including IL-10, IL-1β, AKR7A2, GSTM1, IL-6, IL-8 and C5aR in post-AFB₁ treated MDDCs was only slightly changed. The results indicate that an environmentally relevant level of AFB₁ impairs the phagocytosis capacity of MDDCs and dysregulates the key functions in these pivotal immune cells. This could provide a mechanistic explanation for the observed *in vivo* immunotoxicity associated with this mycotoxin, and further emphasize the essential need for reduction of AFB₁ levels in agricultural commodities.

1. Introduction

Aflatoxins (AFs), secondary metabolites produced mainly by *Aspergillus spp.*, are capable of causing various (non)infectious diseases in humans and animals [1–6]. AFB₁ is the most toxic form among AFs family and has a broad range of toxicities leading to mutagenicity, carcinogenicity, and immunosuppression. AFB₁ has been shown to affect hepatocytes [7–10], kidney [11], respiratory system [12], reproductive system [13], leukocytes [3,14–16] and neural cells [4]. To avoid exposure to AFs, authorities employ extensive measurements to monitor its presence in feedstuffs and foods; however, complete remove AFB₁ from foods/feed resources appears to be challenging. This is partly due to the limitation of analytical techniques in detecting naturally occurring levels of AFs in agricultural commodities, secretions and

sera. As such, the AFB₁ levels in feedstuffs can be far higher than that detected by available analytical tools, which is associated with (para) clinical symptoms in animals and humans [17–19].

Further, lipophilic nature of AFB₁ facilitates its bioavailability, easily entering into the bloodstream and immune cells. Inside the cells, AFB₁ is metabolically bio-transformed to a highly active form, AFB₁-epoxide, through the activity of mainly cytochrome p450 (CYP) family enzymes, particularly CYP1A1 and CYP3A4 in monocytes and lymphocytes [2–4,14,16,20]. AFB₁-epoxide easily binds to DNA, RNA and proteins and forms respective adducts [21]. Our previous study has demonstrated that in human monocytes and lymphocytes a member of glutathione-S-transferase superfamily, GSTM1, is more active in AFB₁ detoxification [14].

Monocytes originated from myeloid precursors emigrate to tissues

* Corresponding author at: Section Immunology, Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
E-mail address: mehrzad@ut.ac.ir (J. Mehrzad).

¹ Equally first authors.

² Present address: Research Institute of Modern Biological Techniques, University of Zanjan.

in order to differentiate to macrophage and dendritic cells (DCs) [15,22]. DCs constitute only about 1% of human peripheral blood mononuclear cells (PBMCs) [23]. They are localized in other peripheral tissues where they act as key immune sentinels that continually patrol and sample environmental antigens [24]. DCs bridge innate and adaptive immunity, playing a pivotal role in initiation of several immune responses including phagocytosis, antigen processing and presenting, exclusively T-cell activation and cytokine secretion. Therefore, recognition, engulfing, processing and presenting an antigen are key parameters, which enable DCs to regulate immune responses [25,26]. The pivotal phagocytosis/endocytosis empowers DCs to acquire and present foreign antigens, as well as to stop and suppress immune responses after engulfing a self-antigen, thereby appropriately dictating other key immune cells, especially T-cells [27]. Pathogen associated molecular patterns (PAMPs) via pattern recognition receptors (PRRs) are precisely recognized and internalized into DCs [28,29]. Complement systems and some key immune-molecules like CD64, CD16 and CCR7 also promote phagocytosis capacity of DCs after DCs licensing. This capacity is reduced and DCs migrate to lymph nodes with higher antigen presenting power [30–33]. DCs use different molecules of classes 1 and 2 of major histocompatibility complexes (MHCs) encoded by one gene complex of the cells to stimulate various subsets of T cytotoxic lymphocytes and T helpers, respectively [34]. These monocyte-derived DCs (MDDCs) efficiently bind and present antigen to naive T-cells by up-regulating MHCs I and II with co-stimulatory molecules and cytokine secretion, creating immunological synapses with naive T-cells causing differentiation of naive T-cells into various effector or regulatory T-cell subsets. This in turn drives the ensuing immune response to protect the host from invading pathogens [2,16,24,35].

We have previously shown that exposure to very low and non-cytotoxic concentrations of AFB₁ could stimulate MDDCs toward overexpression of TLR4 and TLR2 and a pro-inflammatory microenvironment, mistakenly leading to the activation of innate and adaptive immunity potentiating leukocytes disarmament and improper immunity [2,16,18]. Pure MDDCs can massively be generated by treating monocytes with granulocyte macrophage stimulating factor (GM-CSF) and interleukin 4 (IL-4) [2,16,18,36]. The MDDCs generation is also facilitated by bacterial lipopolysaccharide, IL-10, tumor necrosis factor alpha (TNF- α) treatment [37], MAPK, and specially NF- κ B [38]. Overexpression of TLRs potentially triggers a signaling pathways that alters DCs phenotype, decreases DCs phagocytosis capacity, and facilitates their migration to lymphoid organs [35,39].

Little is known about the molecular mechanisms associated with the functioning of AFB₁-exposed humDCs (Fig. 1). The study described herein was designed to explore AFB₁-metabolizing enzymes which are responsible for activation and deactivation of AFB₁ in MDDCs, and thus to better understand the pattern of activation and deactivation of AFB₁ in DCs. In addition, we evaluated the phagocytosis capacity of AFB₁-exposed MDDCs and explored the expression pattern of key functional genes involved in migration, antigen presentation, cell survival, and T-cell activation in AFB₁-exposed MDDCs.

2. Materials and methods

2.1. Reagents

AFB₁ was obtained from Sigma-Aldrich chemie (Taufkirchen, Germany) and was dissolved (under a class 2 laminar flow/hood) in 96% ethanol to make a 0.1 mg/ml concentration. Then, it was further diluted in phosphate-buffered saline (PBS). All tissue culture, media and their supplements including RPMI (Roswell Park Memorial Institute), fetal bovine serum, L-glutamine, penicillin/streptomycin, non-essential amino acids and also PBS were purchased from Invitrogen, Life Technologies (Waltham, Massachusetts, USA). Recombinant human cytokines GM-CSF and IL-4 were obtained from R&D system (R&D, Minneapolis, Minnesota). In addition, FITC-loaded polystyrene micro-particles with 0.1 diameters and Annexin-V PI staining kit were obtained from Sigma-Aldrich and Santa Cruz Biotechnology (USA, California) respectively. Ficoll-Paque plus was purchased from Lympholyte (Zierikzee, the Netherlands).

2.2. Blood sampling and experimental design

All experiment procedures for blood sampling and cell culture were approved by the ethical committee of Ferdowsi University of Mashhad. Sodium-heparinized blood was collected and pooled from 20 healthy male volunteers (18–21 years old), from which pool of 2–3 (totally n = 8 pools) were used for PBMCs isolation and then DCs production. PBMCs were isolated as previously described [1–3,14,16,18] with some modifications. Briefly, blood samples were diluted fourfold with PBS and after adding the same volume of Ficoll, they were centrifuged (1100g, 20 °C, 40 min). The PBMCs layer was collected and washed twice with PBS (500 \times g, 4 °C, 5 min). Finally, 3 ml of 10⁷ PBMCs/ml of complete RPMI medium (with > 98% viability) was seeded in a 3 cm




Fig. 1. Associations between AFB₁ and dendritic cells (DCs), phagocytosis, cytokine secretion and cell survival. A search in COREMINE Medical (<http://www.coremine.com>) shows that in total approximately 160 papers have been published to provide evidence for a correlation between AFB₁ and DCs' phagocytosis, cytokine secretion and survival. However, the majority of above papers have been assessing the effect of AFB₁ on cell (mainly non-immune cells) survival with huge controversies, and only 6 papers have been published on mammals' innate myeloid lineage cells specially human DCs and AFB₁ [1–4,14,16,18,40].

diameter culture plate and was incubated for 2 h in a 37 °C incubator (Mettler, Germany) with 95% humidity and 5% CO₂. Adherent cells (more than 95% monocytes) were re-suspended in warm RPMI medium containing 10% FBS, 3 mmol/l L-glutamine, 1% penicillin/streptomycin, 800U GM-CSF/ml, 1000U IL-4/ml, and 50 mM 2-mercaptoethanol (2-ME) as DCs medium and were incubated for 6 days (at 37 °C, 5% CO₂, 95% humidity) [2,16,18]. Transformation of monocytes to DCs was confirmed with CD11c marker. Harvested immature MDDCs yielded 95% CD11⁺ MDDCs with > 90% viability.

In day 5, immature MDDCs with long membrane protrusions (washed with DCs culture media without phenol red, and seeded at 3×10^6 cells/ml in culture plates), were treated with 0 or 10 ng of AFB₁/ml for 2 and 12 h (37 °C, 5% CO₂, 95% humidity). Phenol red-free media were used to avoid any possible AFB₁-phenol red interactions during DCs exposure and also any potential fluorescence emission from phenol red in flow cytometric assays [2,16,18,40]. The suspensions of MDDCs were then centrifuged (350g, 5 min, 4 °C) and the cells were used for cellular and molecular analyses.

2.3. Quantification of the expression of gene families in DCs

After appropriate AFB₁ exposure, total RNA was extracted from 2×10^6 MDDCs. Briefly, RNA was purified from treated and control MDDCs using TriPure isolation reagent (Roche Diagnostics, Indianapolis, IN). The purified RNA was dissolved in nuclease-free water (Promega, Madison, WI) and immediately stored at –80 °C for later PCR analyses. Before freezing, the concentration and quality of the RNA was determined using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Langensfeld, Germany) and gel electrophoresis, respectively. About 2 µg of the isolated RNA from each cell group was used for first strand cDNA synthesis using RevertAid First Strand cDNA Synthesis Kit (Fermentas, Finland) with 10 pmol of oligo-dT primers. Exon junction or intron-spanning primers were designed for 25 pairs of primers for AFB₁ metabolism, cytokines, function, and TLRs related genes in MDDCs (see details at Table 1). ACTB was used as the reference gene throughout this experiment. Each RT-qPCR reaction was performed in a 20 µl final volume containing 10 pmole of forward and reverse primers, 4 µl 5 × HOT FIREPol® EvaGreen® qPCR master Mix Plus (Solis BioDyne, Tartu, Estonia), and 1 µl (500 ng) cDNA template in CFX Connect™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc, USA). To optimize the qPCR assays, amplification efficiency was calculated for each gene using ten-fold serial dilutions of its cDNA. qPCR conditions for all genes were carried out (in duplicate) with a cycling program including holding for 15 min at 95 °C, followed by cycling 45 times at 94, annealing temperature (Ta) of 53–62 °C (dependent on the primers, see Table 1), and 72 °C (20 s for each temperature). Fluorescent signal was acquired during each extension phase. Melting curve analyses included ramping from 50 – 99 °C, rising 0.5 °C/step and waiting 10 s for each step. A single peak was obtained in each qPCR product reaction which was accompanied by agarose gel electrophoresis to ascertain the specificity of the reactions or the absence of non-specific PCR products (data not shown).

Normalization and analyses of qPCR data were calculated using GenEX Version 5 software (MultiD, Göteborg, Sweden) and Relative Expression Software Tool (REST; QIAGEN, Hilden, Germany). In each qPCR reaction, the cycle number at which the fluorescence rose appropriately above the background was determined as the crossing point (CP). Means of CP duplicates in each qPCR and eight biological repeats were calculated. Optimization experiments were also performed to ensure that the efficiency of the target and the reference genes was approximately equal. A Pfaffl equation [41] was first used to calculate relative gene expression ratio, i.e., the change in each target gene expression divided by the change in ACTB expression. A slope was determined from the exponential phase. Amplification efficiency (E) was calculated based on slope, where $E = 10^{[-1/\text{slope}]}$. The expression of each target gene was calibrated to that of ACTB using the formula:

$$\text{Relative fold change (RCF)} = \frac{\{(E_{\text{target gene}})^{(\text{Control CP}_{\text{target gene}} - \text{treated CP}_{\text{target gene}})}\}}{\{(E_{\text{ACTB}})^{(\text{Control CP}_{\text{ACTB}} - \text{treated CP}_{\text{ACTB}})}\}}.$$

2.4. Flow cytometry-based assessment of AFB₁ impact on phagocytosis capacity of DCs

To determine the effect of AFB₁ on the functional activity of MDDCs, 10⁷ fluorescein isothiocyanate (FITC)-loaded polystyrene microparticles (1.0-µm, 20 beads/MDDCs; Sigma) were added to 10⁶ MDDCs that had been treated/incubated with/without AFB₁ for 2 and 12 h at 37 °C in 6-well culture plates. After 3 h of culture at 37 °C, the MDDCs were then harvested on ice, washed with ice-cold PBS, and were assessed by flow cytometry [minimum event count/sample = 10,000] for internalization of particles. Results were recorded as mean fluorescence intensity (MFI, intensity of phagocytosed FITC-labeled microparticles). The number of FITC⁺ DCs reflected the number of DCs that could phagocytize microparticles and so reflected the phagocytic ability of the MDDCs.

2.5. Flow cytometry-based analyses of apoptosis and necrosis of DCs

The MDDCs survival assay was performed as previously described with some modifications [2,16,40]. Annexin V-FITC and propidium iodide (PI) [Annexin V-PI kit (Sc-45552, Santa Cruz)] were applied on suspension of MDDCs to detect phosphatidylserin, an early apoptotic marker, and to label permeable cells as necrotic cells. Briefly, 10⁵ MDDCs which were incubated for 2 and 12 h at 37 °C in the presence of the aforementioned concentration of AFB₁ in culture medium were incubated with 1 µg Annexin V in 100 µl assay buffer (included in kit) and 10 µl PI for 15 min at room temperature. Flow cytometry control samples were prepared by exposing the cells to Annexin V or PI alone, or neither. After incubation, 400 µl 1X assay buffer was added to each sample and the annexin V/PI apoptosis assays were conducted using single laser emitting light at 488 nm for FITC and PI. 10000 cells were gated using a FACSCalibur System (Beckton Dickinson, Franklin Lakes, New Jersey). To create quadrants, flow cytometry data were analyzed with FCS Express 5 Plus and flowing software (De Novo software).

2.6. Statistical methods

Mean fluorescent intensity for phagocytosis, apoptosis and necrosis were pre-analyzed for normality and homogeneity tests using SPSS 22. ANOVA and LSD multiple comparison tests were used to compare phagocytosis capacity between treatments. Pre-processing qPCR data and ANOVA were analyzed in GenEx and SPSS ver22, respectively. Results were normalized to ACTB gene expression. Three groups of qPCR data were analyzed using one-way ANOVA and Dunnett's multiple comparison test after data were tested for normality and variance homogeneity. $P \leq 0.05$ was considered significant.

3. Results

3.1. Effects of AFB₁ on the expression of gene families in DCs

The effects of naturally occurring levels of aflatoxin (AF) B₁ on the expression of key molecules and function of dendritic cells (DCs) were investigated on human monocyte-derived DCs (MDDCs) by cell culture, RT-qPCR, and flow cytometry. An environmentally relevant level of AFB₁ remarkably impaired the phagocytic capacity of MDDCs. Furthermore, AFB₁ significantly affected the transcript levels of some key functional genes in MDDCs. It caused an up-regulation of key transcripts in cytochrome P450 (CYP) family, MyD88, NF-κB, TNF-α, TLR2, TLR4, COX-2, HLA-DR, CCR7, CD209, LFA3 and CD16. AFB₁ down-regulated the expression of AhR, TGF-β, CD11c and CD64 within 2–12 h post-exposure. In contrast, the transcription of some other key

Table 1

Primer sequences and characteristics for expression analysis of different categories of genes involved in AFB₁ pathogenesis and effects on monocyte-derived dendritic cells (MDDCs) (for detailed information please see the methodology of the qPCR).

Group of genes	Gene symbol (Acc number)	Primer sequence (5' to 3')	Amplicon (bp)	Annealing temperature (°C)
AFB ₁ metabolism	CYP1A1 (NM_000499)	F: CCCAGGGTACAGAGAAAGA R: GAAGGGGACGAAGGAAGA	144	56
	CYP1B1 NM_000104	F:GTCAATGTCACTCTCAGA R:TTGCCTCTTGCTTCTTAT	95	60
	CYP3A4 NM_017460	F:TGGAGATGTGTGGTGAG R:TGTGGATTGTTGAGAGAG	144	54
	AKR7A2 NM_003689	F:GCCAGTCCGAGACCATCC R:TGCAGCCTCTTCAATGACG	154	53
	GSTM1 NM_000561	F:GCAGGAAACAAGGGCTTGGA R:CCTACTTGTGCCCCAGACA	103	58
TLRs-related genes	TLR4 NM_138554	F:GAGGCCATTATGCTATGT R:TTTCTCCCTTCCTCCTTT	143	55
	TLR2 NG_016229	F:AACITCAATCCCCCTTC R:CACCACTCACTCTTCACA	146	59
	Myd88 NM_001172569	F:ACAGAGAGAGGAAGAGAG R:GAAGGAGAGAGGGAGAGA	77	57
	NF-kb NM_003998	F:TGCTGGAGTTCAAGATAAC R:GGATGATTGCTAAGTGAAGAC	179	58
	Cox-2 NM_000963	F:TTGAAGAACTTACAGGAGAA R:GCAGGAGAAACATATAACATTAC	196	58
MDDCs functional genes	CD64 NM_000566	F:CCCCAGCTACAGAATCA R:ACACCAGCTTATCCTTCCA	198	55
	CD16 NM_001271036	F:ACAAACCTCTCCACCCCTC R:TCCTCCTTGAACACCCAC	92	58
	AHR NM_020731	F:ATATCCGAATGATTAAGACT R:CTTCCTCATCTGTTAGTG	162	57
	NQO1 NM_000903	F:AGGAGTTGATGATTGGG R:GGCATAGGGCTTAGACGT	142	56
	HLA-DRB5 NM_002125	F:GACTTCACCCAACAGGACTC R:AAGAATAAGAGCCAAGCAGGAA	111	62
	LFA-3 NM_001779	F:TATGTGCTTGAGTCTCTTCC R:CGATGGCTGTTGTAATGC	101	60
	CD209 NM_021155	F:CTGAGGAGCAGAACTTCC R:GCCATTGCCACTAAATTCC	200	61
	C5aR1 NM_001736	F:ACCAGAACATGAACCTCTT R:GCAGCGTGTTAGAAGTTT	108	57
MDDCs cytokines	IL-6 NM_000600	F:CACCTCTTCAGAACGAATTG R:GGCAAGTCTCCTCATTGA	194	55
	IL-10 NM_000572	F:TGGAGGACTTTAAGGGTTAC R:GATGTCTGGGTCTTGGTT	104	54
	IL-8 NM_000584	F:TTTGAAGAGGGCTGAGAAT R:ACAATACATGAAGTGTGAAGT	122	62
	TNF-alpha NM_000594	F:CTCAGCCTCTTCTCCTTC R:GGGTTTGCTACAACATGG	111	58
	TGF-beta NM_000660	F:TTTGATGTCACCGGAGTTGT R:TAGTGAACCCGTTGATGTCC	130	56
	IL-1b NM_000576	F:GGCTTATTACAGTGGCAATGA R:TAGTGGTGGTCGGAGATTG	135	61
Reference	ACTB NM_001101	F:TGAAGATCAAGATCATTG R:TAACGCAACTAAGTCATA	179	58

genes, including IL-10, IL-1 β , AKR7A2, GSTM1, IL-6, IL-8 and C5aR in post-AFB₁ treated MDDCs was only slightly changed. The results indicate that an environmentally relevant level of AFB₁ impairs the phagocytosis capacity of MDDCs and dysregulates the key functions in these pivotal immune cells. This could provide a mechanistic explanation for the observed *in vivo* immunotoxicity associated with this mycotoxin, and further emphasize the essential need for reduction of AFB₁ levels in agricultural commodities (Fig. 2).

AFB₁ metabolizing genes, specifically AFB₁ activation isoforms, were markedly upregulated in cells exposed to 10 ng/ml AFB₁ for 12 h (Fig. 2A). These genes were CYP3A4, CYP1A1 and CYP1B1. However, no significant changes were detected for the expression of AFB₁ detoxification genes, GSTM1 and AKR7A2. AhR gene was up-regulated after 2 h AFB₁ exposure, but unexpectedly down-regulated after 12 h exposure (Fig. 2A).

The expression of some key TLR-related genes in AFB₁-exposed MDDCs suggested a pro-inflammatory microenvironment. Comparative transcription of AFB₁-exposed MDDCs for two key PRRs, TLR2 and

TLR4, and two TLR signaling pathway molecules, NF-kb and MyD88 along with cyclooxygenase 2 (Cox-2) revealed that 2 h exposure has caused a remarkable upregulation of these genes, except Cox-2, while 12 h exposure upregulated all genes (Fig. 2B).

Genes involved in the function of DCs, CD16, HLA-DR, CCR7, CD209 and LFA3 were significantly up-regulated in MDDCs after exposure to AFB₁, but CD11c and CD64 genes were down-regulated with only slight change on C5aR gene (Fig. 2C).

Analyses on six key cytokine transcripts in MDDCs, showed that AFB₁ was able to somehow affect inflammatory cytokines in DCS (Fig. 2D). A significant down-regulation in mRNA expression of TGF- β and up-regulation in mRNA expression of TNF- α was observed with a slight increase in mRNA expression of IL-1 β , IL-6 and IL-8, but IL-10 was remained unchanged in post-AFB₁ treated MDDCs (Fig. 2C).

3.2. Effects of AFB₁ on the phagocytosis capacity of DCs

The flow cytometry-based phagocytosis assay revealed a significant




Fig. 2. Effects of AFB₁ on the expression of genes related to AFB₁ metabolism and xenobiotic-response genes (A), PRRs (B), key DCs functional genes (C), and some key cytokines (D) in monocyte-derived dendritic cells (MDDCs). The MDDCs were incubated without/with 10 ng/ml of AFB₁ for 2 h and 12 h. We can see a strong over-expression of some key genes induced by AFB₁, (though some unaffected and even down regulated). The relative level of the lowest expression of each gene between all replicates was considered as 1. All data were normalized with *ACTB* as internal control. The data are presented as the mean \pm SD (n = 8). *, ** and *** are confidence level in 5, 1 and 0.1% respectively. Detailed information are available in the methodology of the study with the related References.




Fig. 3. Effects of AFB₁ on monocyte-derived dendritic cells (MDDCs) phagocytosis. Left panel: representative overlay histograms of MDDCs phagocytosis after 2 h (dotted line), 12 h (shaded line) and control (ctrl, filled line) exposing to 10 ng/ml AFB₁. Prolonged AFB₁ cause reduced the number of FITC-coated microbeads particle in the MDDCs. Right panel: overall changes in phagocytosis of AFB₁-exposed and non-exposed (ctrl) MDDCs. The data are presented as the mean \pm SD (n = 8). * is confidence level in 5% (n = 8).

decrease in phagocytosis of FITC-labeled microparticles by post-AFB₁-treated MDDCs (Fig. 3); this finding was consistent with the results acquired on mRNA expression of the opsonin molecule (*i.e.*, CD64) (Fig. 2C). Indeed, AFB₁ caused DCs to be significantly less efficient/potent at uptaking particles/antigens/pathogens. Rate of engulfing particles in 2 and 12 h exposed MDDCs, was markedly lower (~15 and 25%, respectively) than that in control DCs.

3.3. Effects of AFB₁ on apoptosis and survival of DCs

To explore any potential effects of AFB₁ on DCs survival, 10000 MDDCs were analyzed per treatment regimen (Fig. 4). With little effects on DCs necrosis, low levels of AFB₁ significantly ($P < 0.05$) increased DCs apoptosis (Fig. 4). Induction of apoptosis was more intensive at 12 h post-AFB₁ exposure (Fig. 4, lower panel).




Fig. 4. Effects of AFB₁ on apoptosis and necrosis in monocyte-derived dendritic cells (MDDCs). Upper panel: representative flow-cytometric dot plots of MDDCs for control (ctrl), 2 h and 12 h of AFB₁ exposure. Four parts of quadrants show live (lower left), necrotic (upper left), early apoptotic (lower right) and apoptotic-necrotic (upper right) MDDCs. Lower part: overall number of MDDCs in each of quadrant part are showed as histograms. Data are presented as mean \pm SD. Significant differences are indicated by * ($\alpha \leq 0.05$), and ** ($p < 0.01$), respectively (n = 8).

4. Discussion

In order to assess the potential effects of AFB₁ on expression of key genes, phagocytosis capacity, and apoptotic/necrotic states of DCs, MDDCs were exposed to immunobiologically relevant level, ~ 10 ng/ml, of AFB₁ [4–6] within different timepoints in the current study. Because DCs have a high capacity to induce innate and adaptive immune responses, any external signals with a potential to alter the fundamental immune processes of these cells, are able to directly affect the efficacy of immune responses [24,34,35,42]. As DCs are potent to orchestrate adaptive and innate immune responses and induce all aspects of primary and secondary immune responses, small changes in their functions and stability causes major effect on essential immune responses. Here we demonstrate that AFB₁ significantly interferes with canonical functions of MDDCs. This is in line with our previous functional and proteomics studies in porcine [2,16] and human [18] MDDCs. Once activated by antigen, myeloid DCs undergo maturation into competent antigen-presenting cells and migrate to nearby organized lymphoid organs. In these lymphoid organs, T cells specifically recognize the processed antigen presented on the surface of DCs [35,43]. Naturally relevant level of AFB₁ [4–6] is able to deregulate these fundamental immune functions in mammalian DCs.

As expected we found that 2 h challenge of MDDCs with AFB₁ produced more pronounced effect on over-expression of TLR2 and TLR4. It seems prolonged exposure partially triggers immunotolerance disturbances towards more over-expression of PRRs. Our dynamic tests of AFB₁ on other immune cells and species also showed AFB₁ induced more responses in PRRs in early h of exposure. Indeed, AFB₁ interferes

with many routine functions of immune cells through deregulation of PRRs genes expression, decrease of intracellular ROS production capacity, increase in apoptotic cells, cell arresting, and etc. [2,3,14,16,18,40,44].

TLRs and their related genes are highly expressed on the cell surface of DCs; thereby, their mRNA up-regulation could trigger inflammatory responses. In this study we focused on the effects of the AFB₁ on TLR-related mRNA abundance in human MDDCs. Nevertheless, the molecular pathways underlying these findings remain elusive.

Of interest to us was to assess the gene expression of DCs' key opsonin receptor, CD64, when challenged with AFB₁. The *in vitro* experiment herein confirmed that low and non-toxic level of AFB₁ down-regulated expression of pro-phagocytosis gene, CD64 mRNA, in human MDDCs. This might explain the impaired phagocytosis capacity in AFB₁-exposed mammalian DCs as has been shown in this study and also reported by others [2,16]. Until recently the effect of AFB₁ on the CD64 mRNA abundance in human DCs was unclear.

One of the most important factors regarding to efficacy of a toxic substances is their potency in inducing cell death, i.e., necrosis/apoptosis, [40]. Therefore, we assessed flow cytometry-based necrosis/apoptosis in MDDCs induced by AFB₁ (see Fig. 4). We demonstrated for the first time that AFB₁ changes the maintenance of homeostasis of human MDDCs by inducing apoptosis. It also changes cytokines secretions and diminishes phagocytosis capacity and its related molecules. We also showed that 10 ng/ml AFB₁ affects the secretory properties of MDDCs by producing pro-inflammatory cytokine's mRNA, *TNF- α* , whereas it did not alter mRNA expression of IL-1 β or IL-6, IL-8 and IL-10. Here we did not assess the protein levels of cytokines, but we

recently did such assessment on key PRRs and ILs in human DCs at both mRNA and protein levels [18], and also on key ILs at the protein levels in porcine DCs [2,16] supporting the role of AFB₁ in over-expressing key pro-inflammatory cytokines. We also, for the first time, observed a trend for mRNA over-expression of CCR7, CD209 and LFA-3, with little change on C5aR mRNA in AFB₁-exposed MDDCs. It should be mentioned that we analyzed only one complement component, requiring further works on other complement components.

Cytochrome P450 possess mixed function of oxidation and has major role in metabolism conversion of naturally occurring materials in dietary compounds above all AFB₁ [22,45,46]. Thus suppression of activation members of this superfamily enzymes has big impact on AFB₁ characterizations in immune system [3,14]. Our previous studies demonstrated that very low dose of AFB₁ increased gene expression of CYP1A1 in monocytes and CYP3A4 and CYP1B1 in lymphocytes mostly in 2 h of challenge (shorter time of exposure). Further, GSTM1 is transcribed more than AKR7A2 in AFB₁-exposed human monocytes and lymphocytes. Therefore, herein over-expression of CYP3A4, CYP1B1 and CYP1A1 in MDDCs after 12 h of AFB₁ exposure is not surprising. This up-regulation in CYP family causes a positive feedback in AFB₁ activation leading to more oxidative stress in immune cells [40,47].

Previously, it has been shown that TGF- β production and antigen presenting in DCs have indirect correlation. In this study, decrease in TGF- β gene expression in MDDCs due to AFB₁ exposure is in consistent with upregulation of HLA-DR and probably increase in MDDCs antigen presenting capacity [48].

DCs maturation and executive licensing require up-regulation of key chemokine receptor CCR7. CCR7 and IL-10 secretion by DCs can regulate migratory rate of DCs and also antigen presenting function of DCs in an autocrine manner [49]. Thus, AFB₁ could contribute to pseudolicensing direction of immature MDDCs, leading to further DCs maturation involving in over-expression of CCR7, which in turn facilitates DCs migration to the lymphoid tissue. Indeed, one of the major signs for MDDCs licensing is reduction of their phagocytosis capacity. In this scenario they no longer are able to efficiently engulf antigens by receptor-dependent phagocytosis and micropinocytosis (see schematic Fig. 5). The observed prolonged AFB₁ exposure of MDDCs further deteriorated their phagocytosis capacity. Down-regulation of key phagocytic element, CD64 mRNA confirms the observed diminished

phagocytosis in AFB₁-exposed MDDCs [50–52].

Over-expression of TLRs-related genes, particularly MyD88 in AFB₁-exposed MDDCs might lead to activation of TLRs signaling pathway [2,16,18]. Though the molecular size of AFB₁ is very small and is hardly an immunogenic substance, it up-regulated and triggered TLR4 signaling pathways in MDDCs, similar to LPS-treated DCs [18]. LPS is a well-characterized TLR4 ligand that induces DCs maturation and has been shown to induce downregulation of MDDCs phagocytosis [53,54] as well. Also, it is well known that after detection of PAMP by PRR, large number of cytokines including TNF- α , IL-1 β and IL-12 are released which is in line with our finding [2,16,54].

Key pro-inflammatory cytokines, TNF- α and IL-1 β , play major roles in resistance against infections and tumors. IL-12 promotes T-cell activation, particularly T-helper proliferation [36,37,52]. Decrease in T-cell activation after AFB₁ exposure has been previously shown in porcine MDDCs [2,16]. Here, our results show that AFB₁ significantly up-regulated TNF- α , but not other cytokines. Also, TGF- β mRNA, as a key anti-inflammatory cytokine, was down-regulated in MDDCs after short time of exposure to AFB₁ with up-regulation of TNF- α , TLR4, MyD88 and Cox-2. This further emphasizes on the pro-inflammatory micro-environment of AFB₁-exposed MDDCs. In this study, we did not assess the pro-inflammatory cytokines of AFB₁-exposed MDDCs at protein level. However, we have previously found that AFB₁ induces pro-inflammatory cytokines at protein levels in human [18] and porcine [2,16]; significant in-depth comparative works, nonetheless, is required to better understand and interpret the current findings.

The finding herein also showed NF- κ B gene expression was increased after 2 h of AFB₁ exposure. NF- κ B possess two subunits, and when dimerizes their functions are identical. NF- κ B is a major transcription factor in regulation of immune molecules [22,38]. Furthermore, it is a key element in the regulation of the development, maturation and function of DCs. Some reports show a positive co-expression of NF- κ B and HLA-DR, CD80 and CD86 as part of APC function, which is in accordance to our finding. The stimulatory effect of AFB₁ on NF- κ B could be important for modulation of DCs differentiation and function.

After 2 h of AFB₁ exposure, phagocytosis capacity of MDDCs and HLA-DR mRNA level, as indicators of APC function, was decreased and increased, respectively. Thus, it seems that AFB₁ potentiates DCs




Fig. 5. Schematic diagram depicting how the proposed issue of pseudolicensing of AFB₁-exposed monocyte-derived dendritic cells (MDDCs) creates/leads to immunodisregulation *in vivo*. Though mRNA expression of CCR7, CD209 and LFA tended to increase/change, nevertheless the protein levels of those molecules should be evaluated for future prospective.

migration toward tissues and secondary lymphoid organs. This phenomenon potentially breaks immune tolerance and cause autoimmune and allergic problems, suggesting that AFB₁-induced MDDCs maturation might act as an immunogen to increase autoimmune and allergic diseases. However, further fundamental and immunoclinical studies are needed to confirm this.

Overall, the differences found in mRNA expression of candidate molecules in this study cannot be immediately considered as a full reflection of protein expression; thereby, more research at protein levels are needed. Although our findings are at transcriptional and functional levels, they show that AFB₁-exposed MDDCs fail to appropriately orchestrate bridging the innate and adaptive immune responses to various pathogens. Moreover, current molecular assays reveal that AFB₁ breaks the tolerance and fastens DCs maturation. Considering the broad roles of DCs in immunobiology, and the observed dysregulatory impacts of very low and non-toxic concentration of AFB₁ on several fundamental immune processes of DCs, this study provides another compelling reason to avoid AFB₁ exposure. As such, authorities should certainly lower the tolerable limits of AFs in agricultural commodities and foods. Our findings reveal several molecular mechanisms involved in immunodysregulation and immunotoxicity after AFB₁ exposure in humans.

Conflict of interest

None declared.

Acknowledgements

We gratefully acknowledge Ferdowsi University of Mashhad, Mashhad, Iran for financially supporting of this study. We would like to thank Dr Adel Pezeshki, Oklahoma State University, for his constructive English revision and correction.

References

- [1] A.M. Malvandi, J. Mehrzad, M. Saleh-moghaddam, Biologically relevant doses of mixed aflatoxins B and G up-regulate MyD88, TLR2: TLR4 and CD14 transcripts in human PBMCs, *Immunopharmacol. Immunotoxicol.* 35 (2013) 528–532.
- [2] J. Mehrzad, B. Devriendt, K. Baert, E. Cox, Aflatoxin B1 interferes with antigen presenting capacity of porcine dendritic cells, *Toxicol. In Vitro* 28 (2014) 531–537.
- [3] A. Bahari, J. Mehrzad, M. Mahmoudi, M.R. Bassami, H. Dehghani, Cytochrome P450 isoforms are differently up-regulated in aflatoxin B1-exposed human lymphocytes and monocytes, *Immunopharmacol. Immunotoxicol.* 36 (2014) 1–10.
- [4] J. Mehrzad, A.M. Malvandi, M. Alipour, S. Hosseinkhani, Environmentally relevant level of aflatoxin B1 elicits toxic pro-inflammatory response in murine CNS-derived cells, *Toxicol. Lett.* 279 (2017) 96–106.
- [5] S. Viegas, L. Veiga, P. Figueredo, Occupational exposure to aflatoxin B1 in swine production and possible contamination sources, *J. Toxicol. Environ. Health A* 76 (2013) 944–951.
- [6] J.M. Hernandez Hierro, R.J. Garcia-Villanova, P. Rodriguez Torrero, I.M. Toruno Fonseca, Aflatoxins and Ochratoxin A in red paprika for retail sale in Spain: occurrence and evaluation of a simultaneous analytical method, *J. Agric. Food Chem.* 56 (2008) 751–756.
- [7] M.A. Abdel-Wahhab, E.A. Omara, M.M. Abdel-Galil, N.S. Hassan, S.A. Nada, A. Saeed, M.M. el-Sayed, Zizyphus spina-christi extract protects against aflatoxin B1-initiated hepatic carcinogenicity, *Afr. J. Tradit. Complement. Altern. Med.* 4 (2007) 248–256.
- [8] I. Ayed-Boussema, J.M. Pascucci, P. Maurel, H. Bacha, W. Hassen, Effect of aflatoxin B1 on nuclear receptors PXR CAR, and AhR and their target cytochromes P450 mRNA expression in primary cultures of human hepatocytes, *Int. J. Toxicol.* 31 (2012) 86–93.
- [9] A.P. Li, A. Uzgar, Y.S. LaForge, Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1, cyclophosphamide and tamoxifen, *Chem. Biol. Interact.* 199 (2012) 1–8.
- [10] R.A. Towner, S.Y. Qian, M.B. Kadiiska, R.P. Mason, In vivo identification of aflatoxin-induced free radicals in rat bile, *Free Radic. Biol. Med.* 35 (2003) 1330–1340.
- [11] H. Autrup, E.C. Jorgensen, O. Jensen, Aflatoxin B1 induced lacI mutation in liver and kidney of transgenic mice C57BL/6N: effect of phorone, *Mutagenesis* 11 (1996) 69–73.
- [12] P. Larsson, E. Persson, E. Tydén, H. Tjälve, Cell-specific activation of aflatoxin B1 correlates with presence of some cytochrome P450 enzymes in olfactory and respiratory tissues in horse, *Res. Vet. Sci.* 74 (2003) 227–233.
- [13] M. Ortatatli, M.K. Ciftci, M. Tuzcu, A. Kaya, The effects of aflatoxin on the reproductive system of roosters, *Res. Vet. Sci.* 72 (2002) 29–36.
- [14] A. Bahari, J. Mehrzad, M. Mahmoudi, M.R. Bassami, H. Dehghani, GST-M1 is transcribed more than AKR7A2 in AFB-exposed human monocytes and lymphocytes, *J. Immunotoxicol.* 12 (2015) 194–198.
- [15] J.M. Baron, G. Zwadlo-Klarwasser, F. Jugert, W. Hamann, A. Rubben, H. Mukhtar, H.F. Merk, Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets, *Biochem. Pharmacol.* 56 (1998) 1105–1110.
- [16] J. Mehrzad, B. Devriendt, K. Baert, E. Cox, Aflatoxins of type B and G affect porcine dendritic cell maturation *in vitro*, *J. Immunotoxicol.* 12 (2015) 174–180.
- [17] J. Fink-Gremmels, Mycotoxins in cattle feeds and carry-over to dairy milk: a review, *Food Addit. Contam. A* 25 (2008) 172–180.
- [18] A. Mohammadi, J. Mehrzad, M. Mahmoudi, M. Schneider, Environmentally relevant level of aflatoxin B1 dysregulates human dendritic cells through signaling on key toll-like receptors, *Int. J. Toxicol.* 33 (2014) 175–186.
- [19] A. Medina, A. Rodriguez, N. Magan, Effect of climate change on *Aspergillus flavus* and aflatoxin B1 production, *Front. Microbiol.* 5 (2014) 348.
- [20] T.W. Kensler, B.D. Roebuck, G.N. Wogan, J.D. Groopman, Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology, *Toxicol. Sci.* 120 (Suppl. 1) (2011) S28–48.
- [21] L.L. Bedard, T.E. Massey, Aflatoxin B1-induced DNA damage and its repair, *Cancer Lett.* 241 (2006) 174–183.
- [22] M. Ratajowski, A. Walczak-Drzewiecka, A. Salkowska, J. Dastych, Aflatoxins up-regulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor, *Toxicol. Lett.* 205 (2011) 146–153.
- [23] E.R. Mann, D. Bernardo, H.O. Al-Hassi, N.R. English, S.K. Clark, N.E. McCarthy, A.N. Milestone, S.A. Cochrane, A.L. Hart, A.J. Stagg, S.C. Knight, Human gut-specific homeostatic dendritic cells are generated from blood precursors by the gut microenvironment, *Inflam. Bowel. Dis.* 18 (2012) 1275–1286.
- [24] O. Joffre, M.A. Nolte, R. Sporri, C. Reis e Sousa, Inflammatory signals in dendritic cell activation and the induction of adaptive immunity, *Immunol. Rev.* 227 (2009) 234–247.
- [25] K. Bieber, S.E. Autenrieth, Insights how monocytes and dendritic cells contribute and regulate immune defense against microbial pathogens, *Immunobiology* 220 (2015) 215–226.
- [26] C. Wong, D.R. Goldstein, Impact of aging on antigen presentation cell function of dendritic cells, *Curr. Opin. Immunol.* 25 (2013) 535–541.
- [27] A. Iwasaki, R. Medzhitov, Regulation of adaptive immunity by the innate immune system, *Science* 327 (2010) 291–295.
- [28] H. Hemmi, S. Akira, TLR signalling and the function of dendritic cells, *Chem. Immunol. Allergy* 86 (2005) 120–135.
- [29] C. Reis e Sousa, Toll-like receptors and dendritic cells: for whom the bug tolls, *Semin. Immunol.* 16 (2004) 27–34.
- [30] A.L. Amoras, H. Kanegane, T. Miyawaki, M.M. Vilela, Defective Fc_γ, CR1- and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients, *J. Invest. Allergol. Clin. Immunol.* 13 (2003) 181–188.
- [31] A.L. Amoras, M.T. da Silva, R.L. Zollner, H. Kanegane, T. Miyawaki, M.M. Vilela, Expression of Fc gamma and complement receptors in monocytes of X-linked agammaglobulinemia and common variable immunodeficiency patients, *Clin. Exp. Immunol.* 150 (2007) 422–428.
- [32] A. Dubaniewicz, M. Typiak, M. Wybieralska, M. Szadurska, S. Nowakowski, A. Staniewicz-Panasik, K. Rogoz, A. Sternau, P. Deeg, P. Trzonkowski, Changed phagocytic activity and pattern of Fc gamma and complement receptors on blood monocytes in sarcoidosis, *Hum. Immunol.* 73 (2012) 788–794.
- [33] A.L. Hepburn, J.C. Mason, K.A. Davies, Expression of Fc gamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis, *Rheumatology* 43 (2004) 547–554.
- [34] M. Boes, J. Cerny, R. Massol, M. Op den Brouw, T. Kirchhausen, J. Chen, et al., T-cell engagement of dendritic cells rapidly rearranges MHC class II transport, *Nature* 418 (2002) 983–988.
- [35] C. Mousson, J.P. Girard, Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules, *Nature* 479 (2011) 542–546.
- [36] H. Xu, M. Kramer, H.P. Spengler, J.H. Peters, Dendritic cells differentiated from human monocytes through a combination of IL-4: GM-CSF and IFN-gamma exhibit phenotype and function of blood dendritic cells, *Adv. Exp. Med. Biol.* 378 (1995) 75–78.
- [37] K.U. Saikh, A.S. Khan, T. Kissner, R.G. Ulrich, IL-15-induced conversion of monocytes to mature dendritic cells, *Clin. Exp. Immunol.* 126 (2001) 447–455.
- [38] I.F. Tsai, C.Y. Lin, C.T. Huang, Y.C. Lin, C.M. Yang, Y.C. Lin, C.H. Liao, Modulation of human monocyte-derived dendritic cells maturation by a soluble guanylate cyclase activator YC-1, in a cyclic nucleotide independent manner, *Int. Immunopharmacol.* 7 (2007) 1299–1310.
- [39] P.G. Thomas, M.R. Carter, O. Atochina, A.A. Da'Dara, D. Piskorska, E. McGuire, D.A. Harn, Maturation of dendritic cell 2 phenotype by a helminth glycan uses a toll-like receptor 4-dependent mechanism, *J. Immunol.* 171 (2003) 5837–5841.
- [40] J. Mehrzad, G. Klein, J. Kamphues, P. Wolf, N. Grabowski, H.J. Schuberth, In vitro effects of very low levels of aflatoxin B on free radicals production and bactericidal activity of bovine blood neutrophils, *Vet. Immunol. Immunopathol.* 141 (2011) 16–25.
- [41] M.W. Pfaffl, A new mathematical model for relative quantification in real-time RT-PCR, *Nucleic Acids Res.* 29 (2001) e45.
- [42] N. Hymery, Y. Sibiril, D. Parent-Massin, Improvement of human dendritic cell culture for immunotoxicological investigations, *Cell Biol. Toxicol.* 22 (2006) 243–255.
- [43] J. Banchemereau, F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.J. Liu, B. Pulendran,

- K. Palucka, Immunobiology of dendritic cells, *Annu. Rev. Immunol.* 18 (2000) 767–811.
- [44] P.C. Turner, S.E. Moore, A.J. Hall, A.M. Prentice, C.P. Wild, Modification of immune function through exposure to dietary aflatoxin in Gambian children, *Environ. Health Perspect.* 111 (2003) 217–220.
- [45] M. Storvik, P. Huuskonen, T. Kyllonen, S. Lehtonen, H. El-Nezami, S. Auriola, M. Pasanen, Aflatoxin B1 – a potential endocrine disruptor – up-regulates CYP19A1 in JEG-3 cells, *Toxicol. Lett.* 202 (2011) 161–167.
- [46] T. Yanagimoto, S. Itoh, M. Sawada, T. Kamataki, Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1, *Arch. Biochem. Biophys.* 340 (1997) 215–218.
- [47] U. Bernabucci, L. Colavecchia, P.P. Danieli, L. Basirico, N. Lacetera, A. Nardone, B. Ronchi, Aflatoxin B1 and fumonisin B1 affect the oxidative status of bovine peripheral blood mononuclear cells, *Toxicol. In Vitro* 25 (2011) 684–691.
- [48] J.J. Kobie, R.S. Wu, R.A. Kurt, S. Lou, M.K. Adelman, L.J. Whitesell, L.V. Ramanathapuram, C.L. Arteaga, E.T. Akporiaye, Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines, *Cancer Res.* 63 (2003) 1860–1864.
- [49] G. D'Amico, G. Frascaroli, G. Bianchi, P. Transidico, A. Doni, A. Vecchi, S. Sozzani, P. Allavena, A. Mantovani, Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys, *Nat. Immunol.* 1 (2000) 387–391.
- [50] L. Beaudoin, J. Diana, L. Ghazarian, Y. Simoni, C. Boitard, A. Lehuen, Plasmacytoid dendritic cells license regulatory T cells upon iNKT-cell stimulation, to prevent autoimmune diabetes, *Eur. J. Immunol.* 44 (2014) 1454–1466.
- [51] H. Jusforgues-Saklani, M. Uhl, N. Blachere, F. Lemaitre, O. Lantz, P. Bousso, D. Braun, J.J. Moon, M.L. Albert, Antigen persistence is required for dendritic cell licensing and CD8+ T cell cross-priming, *J. Immunol.* 181 (2008) 3067–3076.
- [52] C.M. Smith, N.S. Wilson, J. Waithman, J.A. Villadangos, F.R. Carbone, W.R. Heath, G.T. Belz, Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity, *Nat. Immunol.* 5 (2004) 1143–1148.
- [53] I. Zanoni, R. Ostuni, L.R. Marek, S. Barresi, R. Barbalat, G.M. Barton, F. Granucci, J.C. Kagan, CD14 controls the LPS-induced endocytosis of Toll-like receptor 4, *Cell* 147 (2011) 868–880.
- [54] M. Lu, M. Zhang, R.L. Kitchens, S. Fosmire, A. Takashima, R.S. Munford, Stimulus-dependent deacylation of bacterial lipopolysaccharide by dendritic cells, *J. Exp. Med.* 197 (2003) 1745–1754.